We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $1.85M invested in XTL Biopharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 3 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0.15% less ownership

Funds ownership: 4.74% → 4.59% (-0.15%)

7% less capital invested

Capital invested by funds: $2M → $1.85M (-$149K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$63.7K
2
UBS Group
UBS Group
Switzerland
-$2.25K
3
TRCT
Tower Research Capital (TRC)
New York
-$504

XTLB Hedge Fund Activity: Q4 2015 in Review

4 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2015, worth a combined $1.85M — down 7.4% from $2M a quarter earlier.

Fund positioning in XTLB was balanced in Q4 2015: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.

The largest seller was Sabby Management, cutting an estimated $63.7K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $1.85M of XTL Biopharmaceuticals stock for Q4 2015, down 7.4% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q4 2015 and 0 closed out.
  • The largest XTL Biopharmaceuticals seller in Q4 2015 was Sabby Management, an estimated $63.7K sold.

Based on aggregated 13F filings for Q4 2015.